诱导多能干细胞在血液系统疾病中的研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2016.04.004

生物技术通报 ›› 2016, Vol. 32 ›› Issue (4): 34-38.doi: 10.13560/j.cnki.biotech.bull.1985.2016.04.004

诱导多能干细胞在血液系统疾病中的研究进展

范荻,孙筱放

广州医科大学附属第三医院广东省产科重大疾病重点实验室广东普通高校生殖与遗传重点实验室，广州 510150

收稿日期:2015-07-06 出版日期:2016-04-25 发布日期:2016-04-26
作者简介:范荻，女，硕士研究生，研究方向：生殖与遗传学；E-mail：fandi0725@163.com
基金资助:
国家自然科学基金项目（U1132005），国家自然科学基金项目（31171229）

Research Progress on Induced Pluripotent Stem Cells in Hematopoietic Diseases

FAN Di ,SUN Xiao-fang

The Third Hospital Affiliated to Guangzhou Medical University，Key Laboratory for Major Obstetric Diseases of Guangdong Province，Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes，Guangzhou 510150

Received:2015-07-06 Published:2016-04-25 Online:2016-04-26

摘要/Abstract

摘要： 造血干细胞移植（hemopoietic stem cell transplantation，HSCT）用于血液系统疾病的治疗已取得迅猛发展。但由于供体有限及配型效率不高等问题，严重阻碍了其在临床上的广泛应用。因此，人们迫切地寻求更为安全、经济和有效的造血干细胞的资源。诱导多能干细胞（induced pluripotent stem cells，iPS）在体外可被诱导分化为多种细胞，其中对体外诱导分化为造血干细胞的研究尤为深入。该文就iPS细胞在体外定向分化为造血干细胞及移植研究的最新进展作一综述。

关键词: 造血干细胞移植, 诱导多能干细胞, 造血分化

Abstract: Hematopoietic stem cell transplantation for the treatment of blood system diseases has been had great progress. However，due to the issues of limited donor and matching efficiency is not high，which seriously hindered its wide application in clinic. It is imperative to seek more secure，economical and effective resources of hematopoietic stem cell. Induced pluripotent stem cells can be differentiated into a variety of cells in vitro，especially deeper research on induced differentiation into hematopoietic stem cells in vitro. In this paper，iPS cells directed differentiation to hematopoietic stem cells in vitro and research progress on transplant are reviewed.

Key words: hematopoietic stem cell transplantation, induced pluripotent stem cells, hematopoietic differentiation

范荻,孙筱放. 诱导多能干细胞在血液系统疾病中的研究进展[J]. 生物技术通报, 2016, 32(4): 34-38.

FAN Di ,SUN Xiao-fang. Research Progress on Induced Pluripotent Stem Cells in Hematopoietic Diseases[J]. Biotechnology Bulletin, 2016, 32(4): 34-38.

参考文献

［1］Broxmeyer HE. Cord blood as an alternative source for stem and progenitor cell transplantation［J］. Curr Opin Pediatr, 1995, 7（1）：47-55.
［2］Shibata H, Ageyama N, Tanaka Y, et al. Improved safety of hematopoietic transplantation with monkey embryonic stem cells in the allogeneic setting［J］. Stem Cells, 2006, 24（6）：1450-1457.
［3］Roy L, Bikorimana E, Lapid D, et al. MiR-24 is required for hematopoietic differentiation of mouse embryonic stem cells［J］. PLoS Genet, 2015, 11（1）：e1004959.
［4］Paluru P, Hudock KM, Cheng X, et al. The negative impact of Wnt signaling on megakaryocyte and primitive erythroid progenitors derived from human embryonic stem cells［J］. Stem Cell Res, 2014, 12（2）：441-451.
［5］Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation［J］. Nature, 2009, 461（7260）：86-90.
［6］Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors［J］. Cell, 2007, 131（5）：861-872.
［7］Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons［J］. Science, 2008, 321（5893）：1218-1221.
［8］Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors［J］. Cell, 2007, 131（5）：861-872.
［9］Kaufman DS, Hanson ET, Lewis RL, et al. Hematopoietic colony-forming cells derived from human embryonic stem cells［J］. Proc Natl Acad Sci USA, 2001, 98（19）：10716-10721.
［10］Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors［J］. Cell, 2006, 126（4）：663-676.
［11］Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells［J］. Science, 2007, 318（5858）：1917-1920.
［12］Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells［J］. Stem Cells, 2009, 27（3）：559-567.
［13］Lapillonne H, Kobari L, Mazurier C, et al. Red blood cell generation from human induced pluripotent stem cells：perspectives for transfusion medicine［J］. Haematologica, 2010, 95（10）：1651-1659.
［14］Dias J, Gumenyuk M, Kang H, et al. Generation of red blood cells from human induced pluripotent stem cells［J］. Stem Cells Dev, 2011, 20（9）：1639-1647.
［15］Niwa A, Heike T, Umeda K, et al. A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors［J］. PLoS One, 2011, 6（7）：e22261.
［16］Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin［J］. Science, 2007, 318（5858）：1920-1923.
［17］Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells［J］. Nature, 2009, 460（7251）：53-59.
［18］Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells［J］. Blood, 2010, 115（20）：4039-4042.
［19］Saliba J, Hamidi S, Lenglet G, et al. Heterozygous and homozygous JAK2（V617F）states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients［J］. PLoS One, 2013, 8（9）：e74257.
［20］Song B, Fan Y, He W, et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system［J］. Stem Cells Dev, 2015, 24（9）：1053-1065.
［21］Fulop G, Philips M. The scid mutaion in mice causes a general defect in DNA repair［J］. Nature, 1983, 347（5）：479-482.
［22］Shultz L, Schweitzer P, Christianson L, et al. Multiple defects in innate and adaptive immunological function in NOD/LtSz-scid mice［J］. Immunol, 1995, 154（9）：180-191.
［23］Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells［J］. J Immunol, 2005, 174（10）：6477-6489.
［24］Willinger T, Rongvaux A, Takizawa H, et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung［J］. Proc Natl Acad Sci USA, 2011, 108（6）：2390-2395.
［25］Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients［J］. Blood, 2010, 115（18）：3704-3707.
［26］Ishii M, Matsuoka Y, Sasaki Y, et al. Development of a high-resolution purification method for precise functional characterization of primitive human cord blood-derived CD34-negative SCID-repopulating cells［J］. Exp Hematol, 2011, 39（2）：203-213.
［27］Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood［J］. Cell Stem Cell, 2007, 1（6）：635-645.
［28］Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment［J］. Science, 2011, 333（6039）：218-221.
［29］Osawa M, Hanada K, Hamada H, et al. Long-term lymphohematop-oietic reconstitution by a single CD34-low/negative hematopoietic stem cell［J］. Science, 1996, 273（5272）：242-245.
［30］Morel F, Galy A, Chen B, et al. Characterization of CD34 negative hematopoietic stem cells in murine bone marrow［J］. Blood, 1996, 88（2）：629.
［31］Zanjani ED, Almeida-Porada G, Livingston AG, et al. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells［J］. Exp Hematol, 1998, 26（4）：353-360.
［32］Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration［J］. Science, 2008, 322（5903）：945-949.
［33］Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds［J］. Science, 2013, 341（6146）：651-654.
［34］Ye L, Muench MO, Fusaki N, et al. Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors［J］. Stem Cells Transl Med, 2013, 2（8）：558-566.
［35］Polo JM, Liu S, Figueroa ME, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells［J］. Nat Biotechnol, 2010, 28（8）：848-855.
［36］Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells［J］. Nature, 2010, 467（7313）：285-290.
［37］Sanchez-Freire V, Lee AS, Hu S, et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells［J］. J Am Coll Cardiol, 2014, 64（5）：436-448.
［38］Takahashi M, Matsuoka Y, Sumide K, et al. CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells［J］. Leukemia, 2014, 28（6）：1308-1315.
［39］Reardon S, Cyranoski D. Japan stem-cell trial stirs envy［J］. Nature, 2014, 513（7518）：287-288.

[1]	曾虹, 曾睿琳, 付伟, 吉文汇, 兰道亮. 牛诱导多能干细胞的建立及应用研究进展[J]. 生物技术通报, 2023, 39(5): 130-141.
[2]	薛冰华,刘忠华. 猪多能性干细胞研究进展与前瞻[J]. 生物技术通报, 2015, 31(4): 82-91.
[3]	宋卫华, 刘坤, 赵同标. 诱导多能干细胞研究进展[J]. 生物技术通报, 2014, 0(5): 1-7.
[4]	王凌云;成功;周欢敏;. 动物转基因研究中的技术方法[J]. , 2010, 0(12): 73-77.
[5]	罗庆;宋关斌;袁琳;. 诱导多能干细胞研究进展[J]. , 2009, 0(07): 5-7.

诱导多能干细胞在血液系统疾病中的研究进展

Research Progress on Induced Pluripotent Stem Cells in Hematopoietic Diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价